Stroke pharmacogenomics

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 18, 2009, Pages 2947-2957

  Billeci, Antonia Mr ^a   Agnelli, Giancarlo ^a   Caso, Valeria ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Antiplatelet; Pharmacogenomics; R Tpa; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; CLOPIDOGREL; WARFARIN;

BODY MASS; CANCER RECURRENCE; CEREBROVASCULAR ACCIDENT; CIGARETTE SMOKING; DIABETES MELLITUS; GENE EXPRESSION; GENETIC VARIABILITY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; OBESITY; PHARMACOGENOMICS; PHYSICAL ACTIVITY; REVIEW; RISK FACTOR; STROKE;

HUMANS; PHARMACOGENETICS; PHARMACOKINETICS; POLYMORPHISM, GENETIC; RISK FACTORS; STROKE;

EID: 71449114419     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903386276     Document Type: Review

References (110)

1. Abbott A. You're your genes? Take one of these, three times a day. Nature 2003;425(6960):760-762
2. Evans WE, McLeod HL. Pharmacogenetics-drug disposition, drug target, and side effects. N Engl J Med 2003;348(6):538-549
3. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279(15):1200-1205
4. Phillips KA, Veenstra DL, Oren E, et al. Potential role of pharmacogenetics in reducing adverse drug reactions: a systematic review. JAMA 2001;286(18):2270-2279
5. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003;348(6):529-537
6. Wolfe CD. The impact of stroke. Br Med Bull 2000;56:275-286
7. Adams HP Jr, Woolson RF, Clarke WR, et al. Design of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Control Clin Trials 1997;18(4):358-377
8. Flossman E, Schulz UG, Rothwell PM. Systematic review of methods and results of studies of the genetic epidemiology of ischemic stroke. Stroke 2004;35:212-227
9. Kiely DK, Wolf PA, Cupples LA, et al. Familial aggregation of stroke. The Framingham study. Stroke 1993;24:1366-1371
10. Kissela BM, Sauerbeck L, Woo D, et al. Subarachnoid hemorrhage: a preventable disease with a heritable component. Stroke 2002;33:1321-1326
11. Brass LM, Isaacsohn JL, Merikangas KR, et al. A study of twins and stroke. Stroke 1992;23(2):221-223
12. Wannamethee SG, Shaper AG, Ebrahim S. History of parental death from stroke or heart trouble and the risk of stroke in the middle-aged men. Stroke 1996;27:1492-1498
13. Ayala C, Greenlund KJ, Croft JB, et al. Racial/ethnic disparities in mortality by stroke subtype in the United States, 1995-1998. Am J Epidemiol 2001;154:1057-1063
14. Hademos GJ, Alberts MJ, Awad I, et al. Advances in the genetics of cerebrovascular disease and stroke. Neurology 2001;56:997-1008
15. Natowicz M, Kelley RT. Mendelian etiologies of stroke. Ann Neurol 1987;22:175-192
16. Ruchoux MM, Brulin P, Brillault J, et al. Lessons from CADASIL. Ann NY Acad Sci 2002;977:224-231
17. Ridker PM, Hennekens CH, Lindpaintner K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995;332:912-917
18. Tatlisumak T, Syrjala M, Lndsberg P, et al. FV-ARG-506-GLN-mutation- associated resistance to activated protein C in ischemic stroke. J Stroke Cerebrovasc Dis 1995;5:192-196
19. Rosendaal FR, Siscovick DS, Schwartz SM, et al. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997;90:1747-1750
20. Longstreth WT, Rosendaal FR, Siscovick DS, et al. Risk of stroke in young women and two prothrombiti mutations: factor V Leiden and prothrombin gene variant (G20210A). Stroke 1998;29:577-580
21. Press RD, Liu XY, Beamer N, et al. Ischemic stroke in the elderly. Role of the common factor V mutation causing resistance to activated protein C. Stroke 1996;27:44-48
22. Vandeubrouke JP, Koster T, Brit E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutations. Lancet 1994;344:1453-1457
23. Perry IJ, Refsum H, Morris RW, et al. Prospective study of serum total homocysteine concentrations and risk of stroke in middle-aged British men. Lancet 1995;346:1395-1398
24. Markus HS, Ali N, Swaminathan R, et al. A common polymorphism in the methylenetetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease. Stroke 1997;28:1739-43
25. Carlsson LE, Greinacher A, Spitzer C, et al. Polymorphisms of the human platelet antigens HPA-1,-HPA-2, HPA-3, and HPA-5 on the platelet receptors for fibrinogen (GPIIb/IIIa), von Willebrand factor (GPIb/IX) and collagen (GPIa/Iia) are not correlated with an increased risk for stroke. Stroke 1997;28:1392-1395
26. Wagner KR, Giles WH, Johnson CJ, et al. Platelet glycoprotein receptor IIIa polymorphism P1A2 and ischemic stroke risk: the Stroke prevention in young women study. Stroke 1998;29:581-585
27. Keating MT, Sanguinetti MC. Molecular genetic insights into cardiovascular disease. Science 1996;272:681-685
28. Zareba W, Moss AJ, Schwartz P, et al. Influence of the genotype on the clinical course of the long-QT syndrome. N Engl J Med 1998;339:960-965
29. Schwartz PJ, Priori SG, Locati EH, et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na + channel blockage and to increases in heart rate: implications for gene specific therapy. Circulation 1995;92:3381-3386
30. Donnan GA, Davis SM, Thrift A. The role of blood pressure lowering before and after stroke. Curr Opin Neurol 2003;16:81-86
31. Nicolaou M, DeStefano AL, Gavras I, et al. Genetic predisposition to stroke in relatives of hypertensives. Stroke 2000;31:487-492
32. Lifton RP, Dluhy RG, Powers M, et al. A chimaeric 1 beta-hydroxytase/ aldosterone synthase gene causes glucocorticoid-remediable aldosterism and human hypertension. Nature 1992;355:262-265
33. Shimkets RA, Warnock DG, Bositis CM, et al. Liddle's syndrome: heritable human hypertension causes by mutations in the beat-subunit of the epithelial sodium channel. Cell 1994;79:407-414
34. Bianchi G, Tripodi G, Casari G, et al. Two point mutations within the adducin genes are involved in blood pressure variation. Proc Natl Acad Sci 1994;91:3999-4003
35. Hingorani AD, Jia H, Stevens PA, et al. Renin-angiotensin system gene polymorphism influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens 1995;13:1602-1609
36. O'Donnell CJ, Lindpaintner K, Larson MG, et al. Evidence for association and genetic linkage of the angiotensinconverting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study. Circulation 1998;97:1766-1772
37. Agerholm-Larsen B, Tybjaerg-Hansen A, Frikke-Schmidt R, et al. ACE gene polymorphism as a risk factor for ischemic cerebrovascular disease. Ann Intern Med 1997;127:346-355
38. Ansell BJ. Cholesterol, stroke risk, and stroke prevention. Curr Atheroscler Rep 2000;2:92-96
39. Roses AD. Apolipoprotein E in neurology. Curt Opin Neurol 1996;9:265-270
40. Pedro-Botet J, Senti M, Nogues X, et al. Lipoprotein and apolipoprotein profile in men with ischemic stroke, Role of lipoprotein(a), triglyceride-rich lipoproteins, and apolipoprotein E polymorphism. Stroke 1992;23:1556-1562
41. Nicoll JA, Burnett C, Love S, et al. High frequency of apolipoprotein E epsilon 2 allele in hemorrhage due to cerebral Amyloid: angiopathy. Ann Neurol 1997;41:716-721
42. Greenberg SM, Rebeck GW, Vonsattel JP, et al. Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol 1995;38:254-259
43. Woo D, Sauerbeck LR, Kissela BM, et al. Genetic and environmental risk factors for intracerebral hemorrhage: preliminary results of a populations-based study. Stroke 2002; 33:1190-1196
44. Jeng JS, Sacco RL, Kargman DE, et al. Apolipoproteins and carotid artery atherosclerosis in an elderly multiethnic population: the Northern Manhattan stroke study. Atherosclerosis 2002;165:317-325
45. Sacco RL. Reducing the risk of stroke in diabetes: what have we learned that is new? Diabetes Obes Metab 2002;4 Suppl 1:S27-S34
46. Awata T, Kurihara S, Kikuchi C, et al. Evidence for an association between the class 1 subset of the insulin gene mini-satellite (IDDM 2 locus) and IDDM in the NIDDM. Diabetes 1997;46:1725-1732
47. Yamagata K, Oda N, Kaisaki PJ, et al. Mutations in the hepatocyte nuclear factor-1 alpha gene in maturity onset diabetes of the young (MODY3). Nature 1996;384:455-458 (Pubitemid 26414660)
48. Davies JL, Kawaguchi Y, Bennett ST, et al. A genomewide search for human type 1 diabetes susceptibility genes. Nature 1994;371:130-136
49. Fava D, Gardner S, Pyke D, et al. Evidence that the age oat diagnosis of IDDM is genetically determined. Diabetes Care 1998;21:925-929
50. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke r-tPA Stroke Study Group. N Engl J Med 1995;333(24):1581-1587
51. Molina CA, Montaner J, Arenillas JF, et al. Differential pattern of tissue plasminogen activator-induced proximal middle cerebral artery recanalization among stroke subtypes. Stroke 2004;35(2):486-490
52. Wardlaw JM, Warlow CP, Counsell C. Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke. Lancet 1997;350(9078):607-614 (Pubitemid 27367793)
53. Dubinsky R, Lai SM. Mortality of stroke patients treated with thrombolysis: analysis of nationwide inpatient sample. Neurology 2006;66(11):1742-1744
54. Sheehan JJ, Tsirka SE. Fibrin-modifying serine proteases thrombin, tPA, and plasmin in ischemic stroke: a review. Glia 2005;50(4):340-350
55. Broderick J, Lu M, Jackson C, et al. Apolipoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke. Ann Neurol 2001;49(6):736-744
56. Ladenvall P, Nilsson S, Jood K, et al. Genetic variation at the human tissue-type plasminogen activator (tPA) locus: haplotypes and analysis of association to plasma levels of tPA. Eur J Hum Genet 2003;11(8):603-610
57. Montaner J, Fernández-Cadenas I, Molina CA, et al. Safety profile of tissueplasminogen activator treatment among stroke patients carrying a common polymorphism (C-1562T) in the promoter region of the matrix metalloproteinase-9 gene. Stroke 2003;34(12):2851-2855
58. Fernández-Cadenas I, Alvarez Sab?́n J, Molina CA, et al. ApoE genotype influences on efficacy and safety of thrombolytic treatment for ischemic stroke. Neurologia 2006;21(4):176-180
59. Fernández-Cadenas I, Molina CA, Alvarez-Sab?́n J, et al. ACE gene polymorphisms influence t-PA-induced brain vessel reopening following ischemic stroke. Neurosci Lett 2006;398(3):167-171
60. González-Conejero R, Fernández-Cadenas I, Iniesta JA, et al. Role of fibrinogen levels and factor XIII V34L polymorphism in thrombolytic therapy in stroke patients. Stroke 2006;37(9):2288-2293
61. Fernandez-Cadenas I, Alvarez-Sabin J, Ribo M, et al. Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients. J Thromb Haemost 2007;5(9):1862-1868
62. Aithal GP, Day CP, Kesteven PJL, et al. Association of the polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999;353:717-719
63. Miners JO, Birkett DJ. Cytochrome P45029: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998;45:525-538
64. Rettie AE, Wienkers LC, Gonzales FJ, et al. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994;4:39-42
65. Crespi CL, Miller VP. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH: cytochrome P450 oxidoreductase. Pharmacogenetics 1997;203-210
66. Takahashi H, Kashima T, Nomoto S, et al. Comparisons between in vitro metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics 1998;8:365-373
67. Taube J, Halsall D, Baglin T. Influence of cytochrome P450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000;96:1816-1819
68. Ablin J, Cabili S, Eldor A, et al. Warfarin therapy is feasible in CYP2C9*3 homozygous patients. Europ J of Inter Med 2004;15:22-27
69. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005;352(22):2285- 2293
70. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86
71. Fontana P, Dupont A, Gandrille S, et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequenze variations in healthy subjects. Circulation 2003;108:989-995
72. Fontana P, Gaussem P, Aiach M, et al. P2Y12, H2 haplotype is associated with peripheral arterial disease: a case-control study. Circulation 2003;108:2971-2973
73. Lordkipanidzè M, Pharand C, Palisaitis DA, et al. Aspirin resistence: truth or dare. Pharmacology Therapeutics 2006;112:733-743
74. Andrioli G, Minuz P, Solero P, et al. Defective platelet response to arachidonic acid and thromboxane A(2) in subjects with Pl(A2) polymorphism of beta(3) subunit (glycoprotein IIIa). Br J Haematol 2000;110:911-918
75. Szczeklik A, Undas A, Sanas M, et al. Relationship between bleeding time, aspirin and the PlA1/A2 polymorphism of platelet glycoprotein IIIa. Br J Haematol 2000;110:965-967
76. Undas A, Brummel K, Musial J, et al. PlA2 polymorphism of beta-3 integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation 2001;104:2666-2672
77. Jefferson BK, Foster JH, McCarthy JJ, et al. Aspirin resistance and a single gene. Am J Cardiol 2005;95:805-808
78. HetheringtonSL,SinghRK,LodwickD,etal. Dimorphismin the P2Y1ADPreceptor gene is associated with increased platelet activation response to ADP. Arterioscler Thromb Vasc Biol 2005;25:252-257
79. Terres W, Weber K, Kupper W, et al. Age, cardiovascular risk factors and coronary heart disease as determinant of platelet function in men: a multivariate approach. Thromb Res 1991;62(6):649-661
80. Opper C, Clement C, Schwarz H, et al. Increased number of high sensitive platelets in hypercholesterolemia, cardiovascular disease, and after incubation with cholesterol. Atherosclerosis 1995;113(2):211-217
81. Rosenson RS, Tangney CC. Antithrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998;279(20):1643-1650
82. Hamet P, Skuherska R, Pang SC, et al. Abnormalities of platelet function in hypertension and diabetes. Hypertension 1985;7:135-142
83. Kjeldsen SE, Rostrup M, Gjesdal K, et al. The epinephrine-blood platelet connection with special reference to essential hypertension. Am Hearth J 1991;122:330-336
84. Jimenez AH, Tofler GH, Chen X, et al. Hemodynamic and hemostatic responses to morning and evening exertion in systemic hypertension and implications for triggering of acute cardiovascular disease. Am J Cardiol 1994;74:253-257
85. Terres W, Becker P, Rosemberg A. Changes in cardiovascular risk profile during the cessation of smoking. Am J Med 1994;97(3):242-249
86. Reunad SC, Beswick AD, Fehily AM, et al. Alcohol and platelet aggregation: the Caerphilly prospective heart disease study. Am J Clin Nutr 1992;55(5):1012-1017
87. Mori TA, Beilin LJ, Burke V, et al. Interactions between dietary fat, fish, and fish oils and their effects on platelet function in men at risk of cardiovascular disease. Arterioscler Thromb Vasc Biol 1997;17(2):279-286
88. O'Donnel CJ, Larson MG, Feng D, et al. Genetic and environmental contributions to platelet aggregation. The Framingham Heart Study. Circulation 2001;103:3051-6
89. Undas A, Sanak M, Musial J, et al. Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation. Lancet 1999;353:982-983
90. Goodman T, Sharma P, Ferro A. The genetic of aspirin resistance. Int J Clin Pract 2007;61:826-834
91. Goodman T, Ferro A, Sharma P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol 2008;66(2):222-232
92. Feng D, Lindpaintner K, Larson MG, et al. Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 1999;19:1142-1147
93. Goodall AH, Curzen N, Panesar M, et al. Increased binding of fibrinogen to glycoprotein IIIa-proline33(HPA-1, PlA2, Zwb) positive platelets in patients with cardiovascular disease. Eur Heart J 1999;20:742-747
94. Michelson AD, Furman MI, Goldschmidt-Clermont P, et al. Platelet GPIIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation 2000;101:1013-1018
95. Sirotkina OV, Khaspekova SG, Zabotina AM, et al. Effects of platelet glycoprotein IIb-IIIa number and glycoprotein IIIa Leu33Pro polymorphism on platelet aggregation and sensitivity to glycoprotein IIb-IIIa antagonists. Platelets 2007;18:506-514
96. Lasne D, Krenn M, Pingault V, et al. Interdonor variability of platelet response to thrombin receptor activation: influence of PlA2 polymorphism. Br J Haematol 1997;99:801-807
97. Frey UH, Aral N, Muller N, et al. Cooperative effect of GNB3 825C>T and GPIIIa Pl(A) polymorphisms in enhanced platelet aggregation. Thromb Res 2003;109:279-286
98. Cooke GE, Liu-Stratton Y, Ferketich AK, et al. Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination. JACC 2006;47:541-546
99. Simon T, Verstuyft C, Mary-Krause M, et al.; French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360(4):363-375
100. Paciaroni M, Agnelli G, Caso V, et al. Atrial fibrillation in patients with first-ever stroke: frequency, antithrombotic treatment before the event and effect on clinical outcome. Thromb Haemost 2005;3:1218-1223
101. Klungel OH, Stricker BH, Paes AH, et al. Excess stroke among hypertensive men and women attributable to undertreatment of hypertension. Stroke 1999;30(7):1312-1318
102. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008;25(5):457-507
103. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS r-tPA stroke trials. Lancet. 2004;363(9411):768-774
104. Montaner J. Blood biomarkers to guide stroke thrombolysis. J Front Biosci 2009;1:200-208
105. Antithrombotic Trialists' Collaboration: collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86
106. CAPRIE Steering Committee: a randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339
107. Bhatt D, Fox K, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-1717
108. Van Rijn MJ, Van Duijn CM, Slooter AJ. Impact of genetic testing on complex diseases. Eur J Epidemiol 2005;20(5):383-388
109. Shen AY, Chen W, Yao JF, et al. Effect of race/ethnicity on the efficacy of warfarin: potential implications for prevention of stroke in patients with atrial fibrillation. CNS Drugs. 2008;22(10):815-825
110. Connolly SJ, Ezekowitz MD, Yusuf S, et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361(12):1139-1153